Week 2 on Wegovy: separating early wins from real expectations

What did @ci.my.journey actually say?

Cece reported losing 2.5 pounds in her second week on Wegovy after switching from Mounjaro, which she described as having stopped working for her. She said she was "over the moon" and framed her positive experience as a counterpoint to the negativity she sees online about GLP-1 medications. She did not make dramatic medical claims. She did not prescribe doses, promise outcomes, or say Wegovy cures anything. That restraint matters, and it's worth noting.

She also acknowledged directly that "not everyone has the same experience," which is more nuanced than most week-two TikTok updates. Her switch from Mounjaro to semaglutide after hitting what sounds like a weight loss plateau is a recognizable clinical pattern, though she never uses that language.

Does the science back this up?

Early weight loss on semaglutide is well-documented and biologically real. But week two is almost certainly not fat loss. That needs to be said plainly.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed average weight loss of around 14.9% body weight over 68 weeks on 2.4mg semaglutide. Significant, yes. But the mechanism in the first weeks is largely water weight and reduced glycogen stores from eating less, not metabolic change. Semaglutide also takes several weeks to reach its full dose, and week two on Wegovy typically means someone is still on the 0.25mg starter dose, the lowest rung of the titration schedule. Appetite suppression at that dose varies considerably between individuals.

Her note about being in "shark week" (her term for menstruation) adds a real variable. Hormonal fluctuations affect water retention by several pounds across a cycle, which can inflate or deflate early scale numbers in ways that have nothing to do with the medication.

What did they get wrong (or right)?

She got the framing mostly right. Her caution that "it's early days" is accurate and appropriate. She did not overclaim.

What she underplays, understandably for a week-two update, is that early results on GLP-1 medications are notoriously unreliable predictors of long-term outcomes. A 2.5-pound loss in week two can reflect water, bowel habits, or menstrual cycle timing as much as semaglutide itself. The STEP trials show the real signal only becomes clear around weeks 8 to 12.

Her framing of Mounjaro as something that "stopped working" is a common patient experience but is clinically complex. Tirzepatide (Mounjaro) acts on both GIP and GLP-1 receptors. Plateaus can reflect dose ceiling effects, dietary adaptation, or metabolic accommodation. Switching drugs is a legitimate clinical decision, but the idea that one simply stops working while another will not is an oversimplification. Jellinger et al. (2023, Endocrine Practice) noted that plateau management in GLP-1 therapy remains an area of active clinical debate.

What should you actually know?

Week two numbers should not be the basis for any conclusions about whether Wegovy is working for you. Full stop.

Semaglutide's titration schedule exists for a reason. The 0.25mg starting dose is designed to minimize side effects, not maximize weight loss. Most patients do not see clinically meaningful fat loss until they reach the 1mg or higher maintenance dose, typically after several months. The STEP 4 trial (Rubino et al., 2021, JAMA) reinforced this, showing that patients who discontinued semaglutide regained most of their weight, which tells us the drug's effect is dose-dependent and ongoing, not something established in week two.

The menstrual cycle point deserves more attention than it gets in GLP-1 content. Research on luteal phase water retention (Stachenfeld, 2014, Exercise and Sport Sciences Reviews) documents fluctuations of 1 to 5 pounds across a cycle. Tracking weight during "shark week" and attributing those numbers entirely to medication is a common and understandable error.

Cece's broader message, that positive experiences exist alongside negative ones and both are valid, is accurate and reasonable. GLP-1 side effect profiles vary substantially between individuals, and the online discourse does lean heavily toward negative experiences, partly because those are more shareable.